Dana Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.05 Cr
as on 11-12-2024
- Paid Up Capital ₹ 3.81 Cr
as on 11-12-2024
- Company Age 28 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.05 Cr
as on 11-12-2024
- Revenue -7.41%
(FY 2023)
- Profit 266.77%
(FY 2023)
- Ebitda -218.77%
(FY 2023)
- Net Worth 6.54%
(FY 2023)
- Total Assets 31.19%
(FY 2023)
About Dana Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.05 Cr and a paid-up capital of Rs 3.81 Cr.
The company currently has active open charges totaling ₹5.05 Cr.
Gautam Ramesh, Jacky Hathiramani, Abhai Attavar, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239MH1996PTC101669
- Company No.
101669
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Aug 1996
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationMumbai, Maharashtra
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Dana Pharmaceuticals Private Limited offer?
Dana Pharmaceuticals Private Limited offers a wide range of products and services, including Computer and Mobile Softwares & Apps, Security Software, Attendance Management Software, Accounting & Billing Software, Billing Software, Anti Infective Drugs & Medicines, Malaria Medicine, Flavours & Aromatics, Food Grade Chemical.
Who are the key members and board of directors at Dana Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jacky Hathiramani  | Director | 07-Aug-1996 | Current |
| Gautam Ramesh | Director | 07-Aug-1996 | Current |
Abhai Attavar  | Director | 02-Aug-2022 | Current |
| Suresh Parmar | Director | 02-Aug-2022 | Current |
Financial Performance of Dana Pharmaceuticals.
Dana Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 7.41% decrease. The company also saw a substantial improvement in profitability, with a 266.77% increase in profit. The company's net worth moved up by a moderate rise of 6.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dana Pharmaceuticals?
Unlock access to Dana Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Dana Overseas Private LimitedActive 28 years 12 daysGautam Ramesh, Jacky Hathiramani and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 26 Mar 2010 | ₹1.00 Cr | Open |
Indian Overseas Bank Creation Date: 28 Mar 2008 | ₹1.80 Cr | Open |
Indian Overseas Bank Creation Date: 28 Mar 2008 | ₹5.00 M | Open |
How Many Employees Work at Dana Pharmaceuticals?
Dana Pharmaceuticals has a workforce of 8 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dana Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dana Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
